Zepbound Market Impact

Order byBest matchMost fresh

Novo, Wegovy and Zepbound

Zepbound trims more belly fat than Wegovy, study shows

The impact on waistlines is crucial because they are a surrogate measure for the dangerous fat that gets stored around organs in the abdomen.

· 1d

· 2d · on MSN

Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy

BioSpace · 1d

Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

BioSpace12d

Lilly Unfazed as CVS Picks Novo’s Side in Obesity Market Battle

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

11d

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.